Residency · Residency · Pediatrics

Pediatric Heart Failure and Cardiomyopathy

Overview

Pediatric heart failure differs substantially from adult heart failure in etiologies, presentation, and management. Its incidence ranges from 0.87 to 7.4 per 100,000 children, with the highest rates in infants. The leading cause of heart failure in children is structural congenital heart disease, while cardiomyopathy is the primary cause in structurally normal hearts. Cardiomyopathy incidence is 1.1-1.5 per 100,000 children annually. Pediatric heart failure carries significant morbidity and mortality, with cardiac transplantation remaining the definitive treatment for end-stage disease. Most pharmacotherapy is extrapolated from adult trials with limited pediatric evidence.

Etiologies of Heart Failure by Age

Fetal

Fetal heart failure may result from severe anemia (Rh isoimmunization, parvovirus B19), tachyarrhythmias (SVT), structural heart disease (Ebstein anomaly, AV valve regurgitation), twin-twin transfusion syndrome, or viral myocarditis.

Neonate

Neonatal causes include structural CHD (HLHS, critical AS, coarctation, large VSD, AVSD), myocarditis, arrhythmias (SVT, congenital heart block), anemia, arteriovenous malformations (vein of Galen), and myocardial dysfunction from perinatal asphyxia.

Infant/Toddler

In infants and toddlers, large left-to-right shunts (VSD, AVSD) become symptomatic as PVR drops. Anomalous left coronary artery from the pulmonary artery (ALCAPA) classically presents at 2-4 months with ischemic cardiomyopathy. Dilated cardiomyopathy, myocarditis, and Kawasaki disease with coronary aneurysms are additional causes.

Older Child/Adolescent

In older children and adolescents, cardiomyopathy (dilated and hypertrophic), myocarditis (viral and autoimmune), rheumatic heart disease, arrhythmias, residual lesions in repaired CHD, anthracycline cardiotoxicity in cancer survivors, and endocarditis are the primary etiologies.

Clinical Presentation

Infants

Infants with heart failure present with tachypnea, diaphoresis during feeds, prolonged feeding times, poor weight gain, and failure to thrive. Physical examination reveals tachycardia, hepatomegaly, and gallop rhythm (S3). Heart failure in infants is frequently misdiagnosed as bronchiolitis, reflux, or feeding problems.

Older Children

Older children present with exercise intolerance, fatigue, dyspnea on exertion, orthopnea, nocturnal cough, abdominal pain (from hepatic congestion), and peripheral edema (which is less common in children than adults). Syncope suggests arrhythmia or severe obstruction.

<image>Clinical assessment findings in pediatric heart failure comparing infant presentation (tachypnea during feeds, diaphoresis, hepatomegaly, failure to thrive) with older child presentation (exercise intolerance, orthopnea, peripheral edema, gallop rhythm) alongside key diagnostic studies</image>

Ross Classification (Pediatric HF Severity)

The Ross classification adapts the NYHA system for infants and children. Class I is asymptomatic. Class II involves mild tachypnea or diaphoresis with feeding in infants, or dyspnea on exertion in older children. Class III involves marked tachypnea or diaphoresis with feeding, prolonged feeding times, growth failure, or marked exertional dyspnea. Class IV describes symptoms at rest including tachypnea, retractions, grunting, and diaphoresis.

Diagnostic Workup

Chest X-ray evaluates cardiomegaly (cardiothoracic ratio greater than 0.6 in infants, greater than 0.5 in older children), pulmonary vascular congestion, and pleural effusions. ECG may show chamber enlargement, ST-T wave changes, arrhythmias, or low voltage (suggesting myocarditis). Echocardiography is the primary diagnostic tool, assessing ventricular function (normal LV shortening fraction 28-44%, normal ejection fraction 55-70%), chamber dimensions, valvular function, and pericardial effusion.

BNP and NT-proBNP are elevated in heart failure and useful for diagnosis and monitoring, though age-specific reference ranges are needed (neonatal values are normally higher). Troponin is elevated in myocarditis and ischemia (ALCAPA). Cardiac MRI is the gold standard for ventricular volumes, function, and tissue characterization (fibrosis, edema in myocarditis). Endomyocardial biopsy is definitive for myocarditis but has limited sensitivity due to sampling error and is reserved for unclear etiology or suspected rejection in transplant. Metabolic workup (lactate, ammonia, acylcarnitine profile, urine organic acids) is pursued when metabolic cardiomyopathy is suspected.

Cardiomyopathies

Dilated Cardiomyopathy (DCM)

DCM is the most common cardiomyopathy in children (50-60% of cases), characterized by LV dilation with reduced systolic function. The majority of cases (66%) are idiopathic. Identifiable causes include viral myocarditis (enterovirus, adenovirus, parvovirus), familial/genetic mutations (TTN, LMNA, MYH7, TNNT2, accounting for 20-30%), metabolic disorders (fatty acid oxidation defects, mitochondrial disease, carnitine deficiency), neuromuscular disease (Duchenne/Becker muscular dystrophy), toxic causes (anthracycline chemotherapy), nutritional deficiencies (selenium, thiamine, carnitine), and tachycardia-induced cardiomyopathy from persistent SVT or ectopic atrial tachycardia, which is notably reversible with rate control. Outcomes show approximately 30-40% recovery, 30% stabilization, and 30% progression to transplant or death within 2 years.

Hypertrophic Cardiomyopathy (HCM)

HCM is defined as unexplained LV hypertrophy (wall thickness 2 or more standard deviations above the mean for age). It is the most common cause of sudden cardiac death in young athletes, with a prevalence of 1 in 500 (most cases subclinical). Inheritance is autosomal dominant in approximately 60%, with sarcomeric gene mutations (MYH7 and MYBPC3 being the most common). HCM may occur with or without LVOT obstruction; dynamic obstruction worsens with decreased preload (Valsalva, dehydration, standing). Systolic anterior motion (SAM) of the mitral valve contributes to obstruction.

Clinical features include exertional dyspnea, chest pain, syncope, and palpitations. The murmur is a harsh systolic murmur at the left lower sternal border that increases with standing or Valsalva and decreases with squatting. Risk stratification for sudden death considers massive hypertrophy, non-sustained ventricular tachycardia, unexplained syncope, family history of SCD, and abnormal blood pressure response to exercise.

Management involves avoiding dehydration and (controversially) competitive athletics restriction, though 2020 AHA/ACC guidelines allow shared decision-making for some patients. Beta-blockers are first-line, with calcium channel blockers (verapamil) for symptomatic obstruction. Myectomy or alcohol septal ablation addresses refractory obstruction. ICD implantation is indicated for high SCD risk. Mavacamten, a cardiac myosin inhibitor FDA-approved for adults with obstructive HCM, is undergoing pediatric trials.

Restrictive Cardiomyopathy (RCM)

RCM is rare in children (less than 5% of cardiomyopathies), characterized by rigid ventricular walls with impaired diastolic filling but normal or near-normal systolic function. Marked atrial dilation is the hallmark. It carries the worst prognosis of all pediatric cardiomyopathies, with 50% mortality within 2-3 years, often requiring early transplant listing.

Left Ventricular Noncompaction (LVNC)

LVNC features excessive trabeculation of the LV myocardium with deep intertrabecular recesses. It can present with a DCM phenotype, restrictive physiology, or be asymptomatic. Risks include thromboembolism, arrhythmias, and heart failure. Diagnosis is by echocardiography or cardiac MRI assessing the noncompacted-to-compacted ratio.

Medical Management of Pediatric Heart Failure

Diuretics

Furosemide at 1-2 mg/kg/dose PO/IV given 2-3 times daily is the mainstay for volume overload, requiring electrolyte and renal function monitoring. Chlorothiazide at 10-20 mg/kg/dose twice daily is often added for synergistic effect. Spironolactone at 1-2 mg/kg/day provides aldosterone antagonism with potassium-sparing and anti-fibrotic effects.

ACE Inhibitors

Enalapril starting at 0.1 mg/kg/dose twice daily (titrated to 0.5 mg/kg/dose) or captopril at 0.1-0.5 mg/kg/dose three times daily (for infants) provides afterload reduction and neurohormonal modulation. Renal function and potassium require monitoring.

Beta-Blockers

Carvedilol starting at 0.05 mg/kg/dose twice daily and titrated to 0.35 mg/kg/dose is the most common choice. Beta-blockers must be started at low doses and titrated slowly, avoiding initiation during acute decompensation. Pediatric evidence is extrapolated from adult trials, as pediatric RCTs have been underpowered.

Digoxin

Digoxin has a limited current role but may improve symptoms in heart failure with reduced ejection fraction. It has a narrow therapeutic window, dosed at 5-10 mcg/kg/day divided twice daily with target levels of 0.5-0.9 ng/mL.

Inotropes (Acute/Decompensated HF)

Milrinone, a PDE3 inhibitor and inodilator, is first-line for acute pediatric heart failure at 0.25-0.75 mcg/kg/min IV. It improves contractility while reducing afterload, requiring monitoring for hypotension. Dobutamine (beta-1 agonist, 5-20 mcg/kg/min), dopamine (5-10 mcg/kg/min for inotropy), and epinephrine (0.01-0.1 mcg/kg/min for severe cardiogenic shock) are additional options.

Mechanical Circulatory Support

ECMO provides temporary support for acute decompensation (myocarditis, post-cardiotomy failure). Ventricular assist devices serve as a bridge to transplant or recovery: the Berlin Heart EXCOR is a paracorporeal pulsatile VAD for children with FDA humanitarian device exemption approval, and the HeartMate 3 continuous-flow LVAD is used in larger adolescents. VADs have significantly improved waitlist survival and outcomes.

<image>Echocardiographic images comparing normal heart with dilated cardiomyopathy (LV dilation, reduced EF), hypertrophic cardiomyopathy (asymmetric septal hypertrophy with SAM), and restrictive cardiomyopathy (bilateral atrial enlargement with normal LV size), along with cardiac MRI of left ventricular noncompaction</image>

Cardiac Transplantation

Cardiac transplantation is the definitive treatment for end-stage heart failure, with approximately 400-500 pediatric transplants performed annually in the US. Indications include refractory heart failure despite maximal medical therapy, VAD-dependence, unresectable cardiac tumors, and complex CHD not amenable to surgical repair. Median survival is approximately 15-20 years post-transplant. Complications include acute rejection (cellular and antibody-mediated), cardiac allograft vasculopathy (chronic rejection), infection, malignancy (post-transplant lymphoproliferative disorder), and renal dysfunction from calcineurin inhibitors.

Clinical Pearls

Heart failure should be considered in any infant with poor feeding, tachypnea, and diaphoresis because it is frequently misdiagnosed as reflux or respiratory disease. ALCAPA should be suspected in any infant presenting at 2-4 months with a dilated cardiomyopathy pattern; ECG findings of lateral wall ischemia (Q waves, ST changes in leads I and aVL) are the diagnostic clue. Tachycardia-induced cardiomyopathy is reversible, and incessant arrhythmia (ectopic atrial tachycardia, PJRT) should always be evaluated in new DCM. BNP/NT-proBNP is invaluable for diagnosis and monitoring but must be interpreted with age-appropriate reference ranges. HCM is the leading cause of sudden cardiac death in young athletes, and a family history of sudden death under age 50 should prompt cardiac screening. In acute decompensated heart failure, milrinone is preferred over dobutamine because it provides both inotropy and afterload reduction.

Key Controversy: Adult HF Medications in Pediatric Populations

Sacubitril-valsartan (Entresto), an angiotensin receptor-neprilysin inhibitor that is first-line in adult HFrEF, has limited pediatric data. The PANORAMA-HF trial did not meet its primary endpoint in a mixed pediatric heart failure population (CHD and cardiomyopathy), though some centers use it off-label in adolescents with DCM. SGLT2 inhibitors (empagliflozin, dapagliflozin), which have been transformative in adult heart failure, have minimal pediatric data, with trials underway but not yet informative. Ivabradine, a selective sinus node inhibitor, has some positive pediatric data in DCM with growing off-label use. The fundamental challenge is that pediatric heart failure is rare, heterogeneous, and difficult to study, making extrapolation from adult data necessary but imperfect.

References

• Kantor PF, et al. Presentation, Diagnosis, and Medical Management of Heart Failure in Children: CCS Guidelines. Can J Cardiol. 2013;29(12):1535-1552.
• Lipshultz SE, et al. Pediatric Cardiomyopathy: Natural History and Treatment. Curr Opin Cardiol. 2015;30(1):95-103.
• Rossano JW, et al. Prevalence, Morbidity, and Mortality of Heart Failure-Related Hospitalizations in Children. J Card Fail. 2012;18(6):459-470.
• Ommen SR, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of HCM. Circulation. 2020;142(25):e558-e631.
• Hsu DT, et al. Heart Failure in Children. Circ Heart Fail. 2009;2(5):490-498.
• Shaddy RE, et al. Carvedilol for Children and Adolescents with Heart Failure. JAMA. 2007;298(10):1171-1179.

Read this lecture as Markdown